Medicine Recommendations

Following a gastric bypass

Following a sleeve Gastrectomy

Treatment of Clostridium difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults

NICE TA676 - for treating moderate to severe rheumatoid arthritis

MHRA Drug Safety Update, 26 April 2023

JAK Inhibitors MHRA Drug Safety Update

Treating moderately to severely active ulcerative colitis - NICE TA792

NICE TA792 - Filgotinib for treating moderately to severely active ulcerative colitis

MHRA Drug Safety Update, 26 April 2023

JAK Inhibitors MHRA Drug Safety Update

Benign Prostatic Hyperplasia

BJUI - Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia 

Chronic kidney disease in type 2 diabetes - NICE TA877

NICE TA 877 - Finerenone for treating chronic kidney disease in type 2 diabetes

Arrhythmias

Psoriasis

Diabetic macular oedema (NICE TA301)

NICE TA301 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271)

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (NICE TA613)

Fluocinolone acetonide intravitreal implant for treating recurrent noninfectious uvetitis (NICE TA590)

NICE TA 590 - Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis

Prophylaxis of dental caries

Treatment of Actinic Keratosis

Treatment of small superficial basal-cell carcinomas in adults

Premature ejaculation

Depressive illness, Bulimia Nervosa, Obsessive Compulsive Disorder

MHRA Drug Safety Update  - Fluoxetine: possible small risk of congenital cardiac defects

Depressive illness, psychoses

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Schizophrenia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Maintenance in schizophrenia and other psychoses

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.